Skip to content

BCBS Nebraska

Does BCBS Nebraska cover Zepbound?

Yes. BCBS Nebraska covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy on file; the document isn't available to view online yet.

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial approval - weight management

All of:

  • Patient is 18 years of age or older
  • History of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications) for at least 3 months prior to initiating therapy
  • Patient is currently on and will continue a weight loss program of low-calorie diet, increased physical activity, and behavioral modifications
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested dose is within FDA approved dosage limits
  • Requested agent will NOT be used in combination with another weight loss agent

Plus any one of:

  • BMI ≥ 30 kg/m2 (obesity diagnosis)
  • BMI ≥ 27 kg/m2 with at least one weight-related comorbidity/risk factor (e.g., diabetes, dyslipidemia, coronary artery disease)

Documentation to bring

  • Documentation of BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with qualifying comorbidity
  • Documentation of at least 3-month history of participation in a medically supervised weight loss program (low-calorie diet, increased physical activity, behavioral modifications)
  • Attestation that patient is currently on and will continue a weight loss program

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Provider must attest that patient has achieved and maintained weight loss ≥ 5% from baseline (prior to initiation of requested agent). Patient must be currently on and will continue a weight loss regimen. The 3-month medically supervised program requirement is not re-verified at renewal.

Not covered when

  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Bariatric surgery

Policy note: Zepbound added to policy 04-01-2024. Policy description incorrectly labels Zepbound as liraglutide; Zepbound is actually tirzepatide. The weight loss criteria apply under the shared 'Target Agent(s)' framework.

Policy effective July 1, 2023 · verified June 2, 2026 · source: Policy 211

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial approval - OSA

All of:

  • OSA diagnosis confirmed by polysomnography (PSG) or home sleep apnea test
  • AHI ≥ 15 events/hour from baseline (prior to initiation of pharmacotherapy)
  • Requested agent is Zepbound
  • BMI ≥ 30 kg/m2
  • Patient does not have craniofacial abnormalities that may affect breathing
  • Patient does NOT have diagnosis of central or mixed sleep apnea with mixed or central apneas/hypopneas ≥ 50%
  • Patient does NOT have diagnosis of Cheyne Stokes Respiration
  • Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Patient is not pregnant
  • Requested agent will NOT be used in combination with another GLP-1 receptor agonist
  • Requested agent will NOT be used in combination with another weight loss agent

Documentation to bring

  • Polysomnography (PSG) or home sleep apnea test results confirming OSA diagnosis
  • Documentation of AHI ≥ 15 events/hour at baseline
  • Documentation of BMI ≥ 30 kg/m2
  • Documentation that patient does not have craniofacial abnormalities affecting breathing
  • Documentation that patient does not have central/mixed sleep apnea (≥ 50% central/mixed apneas/hypopneas)
  • Documentation that patient does not have Cheyne Stokes Respiration
  • Documentation that patient does not have Obesity Hypoventilation Syndrome or daytime hypercapnia

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must demonstrate clinical benefit with requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Patient must not be pregnant and not currently treated with another GLP-1 receptor agonist.

Not covered when

  • Craniofacial abnormalities that may affect breathing
  • Central or mixed sleep apnea with mixed or central apneas/hypopneas ≥ 50%
  • Cheyne Stokes Respiration
  • Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Combination with another GLP-1 receptor agonist not permitted
  • Combination with another weight loss agent not permitted
  • Pregnancy

Policy note: OSA criteria added 06-30-2025. Only Zepbound is eligible for the OSA indication per policy. No PAP/CPAP prior trial required. Renewal requires clinical benefit evidence (e.g., AHI reduction or improved Epworth Sleepiness Scale score).

Policy effective July 1, 2023 · verified June 2, 2026 · source: Policy 211

Open on its own page →

Questions people ask
Does BCBS Nebraska cover Zepbound?
Yes. BCBS Nebraska covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with BCBS Nebraska?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Nebraska require to renew Zepbound?
Weight Loss — Applies to Employer and ACA Marketplace plans. Provider must attest that patient has achieved and maintained weight loss ≥ 5% from baseline (prior to initiation of requested agent). Patient must be currently on and will continue a weight loss regimen. The 3-month medically supervised program requirement is not re-verified at renewal. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. Patient must demonstrate clinical benefit with requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Patient must not be pregnant and not currently treated with another GLP-1 receptor agonist.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Nebraska: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Molina Healthcare, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS North Carolina

All insurance plans · All medications

Summary of BCBS Nebraska's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.